Trial
NCT00930345
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Pfizer; National Cancer Institute, France
Condition
Metastatic Renal Cell Carcinoma
Intervention
Sunitinib (SUTENT)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-01